Last reviewed · How we verify

NCT04138641

Dutch Cangrelor Registry

Completed Last updated 28 July 2020
What this trial tests

trial testing Cangrelor in STEMI - ST Elevation Myocardial Infarction in 250 participants. Completed in 24 July 2020.

Timeline
17 December 2019
Primary endpoint
24 July 2020
24 July 2020

Quick facts

Lead sponsorIsala
StatusCompleted
Study typeOBSERVATIONAL
Enrollment250
Start date17 December 2019
Primary completion24 July 2020
Estimated completion24 July 2020
Sites1 location across Netherlands

Drugs / interventions tested

Conditions studied

Sponsor

Isala — full company profile →

Who can join

Adults 18 to 110, any sex, with STEMI - ST Elevation Myocardial Infarction or NSTEMI - Non-ST Segment Elevation MI. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cangrelor is a fast and directly acting platelet aggregation inhibitor. It is potentially indicated for several types of patients who are undergoing PCI. A nationwide cangrelor registry has up until now not been performed and with the introduction of cangrelor in the Netherlands its efficacy and safety will be determined.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Cangrelor

Trials testing the same drug.

Other recruiting trials for STEMI - ST Elevation Myocardial Infarction

Currently open trials in the same condition.

Other Isala trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04138641.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing